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Background: Group B Streptococcus (GBS) remains susceptible to penicillin, however, resistance
to second-line antimicrobials, clindamycin and erythromycin, has increased since 1996. We
describe the age-specific antibiotic susceptibility profile and capsular type distribution among
invasive and colonizing GBS strains.
Methods:  We tested 486 invasive GBS isolates from individuals of all ages collected by a
Wisconsin surveillance system between 1998 and 2002 and 167 colonizing strains collected from
nonpregnant college students during 2001 in Michigan. Antimicrobial susceptibility testing was
performed by disk diffusion or Etest and capsular typing was performed using DNA dot blot
hybridization
Results: 20.0% (97/486) of invasive and 40.7% (68/167) of colonizing isolates were resistant to
clindamycin (P < .001) and 24.5% (119/486) of invasive and 41.9% (70/167) of colonizing isolates
were resistant to erythromycin (P < .001). Similarly, 19.8% (96/486) of invasive and 38.3% (64/167)
of colonizing isolates were resistant to both antimicrobial agents (P < .001). 29.4% (5/17) of invasive
isolates from persons 18–29 years of age and 24.3% (17/70) of invasive isolates from persons 30–
49 years of age were resistant to clindamycin. Similarly, 35.3% (6/17) of invasive isolates from
persons 18–29 years of age and 31.4% (22/70) of invasive isolates from persons 30–49 years of age
were resistant to erythromycin. 34.7% (26/75) of invasive isolates from persons < 1 year of age
were capsular type Ia, whereas capsular type V predominated among isolates from adults.
Conclusion: Clindamycin and erythromycin resistance rates were high among isolates colonizing
nonpregnant college students and invasive GBS isolates, particularly among the colonizing isolates.
Susceptibility profiles were similar by age although the proportion of clindamycin and erythromycin
resistance among invasive isolates was highest among persons 18–49 years of age. Increasing
antimicrobial resistance has implications for GBS disease treatment and intrapartum prophylaxis
among penicillin intolerant patients.
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Background
Group B Streptococcus (GBS) (Streptococcus agalactiae) is a
significant cause of neonatal sepsis and meningitis and of
severe infections in pregnant women and nonpregnant
adults with underlying medical conditions [1]. GBS is also
a commensal that colonizes the gastrointestinal and geni-
tourinary tracts. The prevalence of GBS colonization
among pregnant and nonpregnant adults has been esti-
mated at 10% to 40% [2-4]. Transmission from a colo-
nized pregnant woman to her neonate occurs via the
ascending route during labor and delivery [5]. Adminis-
tration of intrapartum antimicrobial prophylaxis (IAP) to
colonized women has resulted in a striking decline in
cases of early-onset and maternal GBS disease [6]. How-
ever, a similar decrease has not been observed for infants
with late-onset disease or nonpregnant adults; currently
there is no established prevention protocol for either
group.
Although GBS remains sensitive to penicillin, the pre-
ferred agent for GBS infections and IAP, an estimated 12%
of pregnant women report having a penicillin allergy [7],
requiring the use of an alternative agent. Resistance to the
second-line antibiotics clindamycin and erythromycin
has increased since 1996 [7-9]. Resistance frequencies cur-
rently range from 6% to 21% for clindamycin and 12% to
29% for erythromycin in the United States [10-12], while
other countries report higher rates [13].
We describe the age-specific antimicrobial susceptibility
profile and capsular type distribution for invasive GBS
strains from individuals of all ages, collected by the Wis-
consin public health surveillance system. For comparison
we included the same information for a collection of
strains from colonized nonpregnant college students 18–
19 years of age. Our goal was to assess whether there are
differences in susceptibility profiles between colonizing
and invasive GBS strains by capsular type. We hypothe-
sized that antimicrobial susceptibility profiles and capsu-
lar types might vary with age. Continuous monitoring of
GBS antimicrobial resistance patterns through surveil-
lance activities and epidemiologic studies will help guide
prophylaxis regimens for penicillin intolerant patients.
Methods
Invasive and colonizing strains
486 invasive strains were collected from 482 patients
through the Wisconsin Division of Public Health, Bureau
of Communicable Diseases, Invasive Bacterial Laboratory
Surveillance System between 1998 and 2002. Forty-nine
percent (234/482) of patients were female. GBS isolates
were shipped by courier from hospital and regional clini-
cal microbiology laboratories to the Wisconsin State Lab-
oratory of Hygiene for initial processing and inclusion in
the surveillance system. Invasive GBS disease was defined
as any GBS infection identified from a normally sterile
site. Approximately 88% of Wisconsin clinical laborato-
ries with invasive bacterial testing capabilities voluntarily
submitted isolates. Four of the 482 patients had two dif-
ferent GBS morphologies isolated from their culture. In
each instance the two morphologies displayed different
capsular types; both morphologies from each patient iso-
late were included in the analysis.
167 colonizing strains, previously described by our group
[14], were included for comparison. Briefly, 882 coloniz-
ing strains were collected from 57 healthy male and 95
healthy, nonpregnant female college students between
January and February of 2001 as part of a cross-sectional
survey. After obtaining written informed consent at
enrollment, a study recruiter collected throat and mouth
swabs. Participants self-collected initial-void urine and
anal orifice specimens, and women collected vaginal spec-
imens using a tampon. Following enrollment, all GBS-
positive participants and a random sample of those nega-
tive for GBS were invited to partake in the four follow-up
visits. Participants were followed at three-week intervals
for a total of 12 weeks. At each follow-up visit participants
provided urine, anal orifice and vaginal (if relevant) spec-
imens. Additional throat swabs were obtained at one of
the four follow-up visits. The Health Sciences Institutional
Review Board at the University of Michigan approved the
study protocol (IRB file number 4133).
PFGE was performed on 882 GBS isolates cultured from
the anal orifice, vagina, urine, throat, and mouth. Separate
dendrograms were constructed, using BioNumerics soft-
ware (Applied Maths, Kortrijk, Belgium), for each partici-
pant to determine which isolates were unique. An isolate
was considered unique if it had > 3 bands that were differ-
ent from the other isolates from that individual. All
unique isolates from each individual were selected for fur-
ther analysis (n = 167).
Antimicrobial susceptibility testing
Each GBS strain was tested for susceptibility to 10 antibi-
otics. Disk diffusion was used to determine the suscepti-
bilities to ampicillin (10 µg), cefazolin (30 µg), imipenem
(10 µg), levofloxacin (5 µg), linezolid (30 µg), penicillin
(10 IU), quinupristin-dalfopristin (15 µg), and vancomy-
cin (30 µg) (Baltimore Biological Laboratories [BBL],
Sparks, MD). GBS was subcultured onto trypticase soy
agar (TSA) with 5% sheep blood (BBL, Sparks, MD) from
frozen culture stocks. Disk diffusion was performed as
described previously [15], while the minimum inhibitory
concentration (MIC) was determined for clindamycin and
erythromycin using Etest strips (AB Biodisk, NA, Piscata-
way, NJ). Clinical and Laboratory Standards Institute
(CLSI, formerly NCCLS) guidelines were used to interpret
disk diffusion and MIC results [16]. The following break-BMC Infectious Diseases 2006, 6:57 http://www.biomedcentral.com/1471-2334/6/57
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points were used for cefazolin (S, ≥ 28 mm; I, 26–27 mm
and R, ≤ 25 mm) [7] and for imipenem (S, ≥ 30 mm).
If an isolate was erythromycin-resistant and clindamycin-
susceptible, we performed a disk induction test or a "D
test", by placing clindamycin (2 µg) and erythromycin (15
µg) disks 15 mm apart and observing for the induction of
clindamycin resistance. The current recommendation is
12 mm [17], however these guidelines were not available
when this testing was performed. An isolate with a clin-
damycin disk diffusion zone blunted on the side closest to
erythromycin was considered inducible.
At the time of our study the CDC and CLSI recommended
disk diffusion testing in 5% CO2 for GBS [8,16]. However,
the "pH effect" of CO2 incubation reportedly reduces zone
sizes (or increases MIC results) for macrolides and has
altered susceptibility interpretations for other organisms
[18,19]. To compare antibiotic activity in O2 to that in
CO2, we tested 36 replicate samples of our control strain,
S. agalactiae (ATCC 12403), and 18 clinical isolates for
susceptibility to multiple antibiotics; half in ambient air
and half in 5% CO2. Although statistically different, the
mean differences in zone sizes for replicate tests in ambi-
ent air compared to 5% CO2 did not exceed a normal
expected zone size variation of 2 mm [20]. This was also
true for differences between technologists with the excep-
tion of imipenem where the mean difference was 2.33
mm. Thus the observed variation by growth condition is
similar to the expected variation by technologist. In short,
the use of CLSI interpretations for zone sizes listed in
standard M100-S12, Table 2H, M2-Disk Diffusion, origi-
nally generated with growth in 5% CO2, can be used for
susceptibility testing in either environment. Thus, we used
ambient air for performing antimicrobial susceptibility
testing of all strains including our control strain.
Capsular typing
The capsular type was determined using DNA dot blot
hybridization as described previously [21]. For a subset of
isolates, however, DNA dot blot hybridization was per-
formed with an alternative anti-fluorescein-AP antibody,
according to the manufacturer's protocol (Roche Diagnos-
tics, Penzberg, Germany); the reagents used previously
were discontinued. Briefly, we used DNA dot blot hybrid-
ization with PCR-generated probes from the GBS capsular
genes for serotypes Ia, Ib and II to VIII. PCR primers were
designed to amplify type-specific GBS capsular gene
sequences. Gene probes were constructed from the PCR
products and subsequently used to classify isolates as cap-
sular type Ia, Ib or II to VIII based on hybridization pro-
files. Nontypeable isolates did not bind to any of the
capsular gene probes, but were probed for the presence of
the GBS 16S RNA gene to verify that chromosomal DNA
was present on the membrane when it was initially
probed with the capsular-specific gene probes.
Three isolates displayed a gene probe homology that was
not consistent with any of the nine serotypes and there-
fore a capsular type could not be assigned based on the
DNA dot blot hybridization profile. These isolates were
termed variable type (VT).
Statistical analysis
The χ2 test was used to examine the frequency of resistance
between the two collections and between resistance and
capsular type or age, while the χ2 test for trend was used to
examine the differences in the frequency of resistance
Table 1: Antimicrobial susceptibility profiles for invasive (Wisconsin 1998–2002) and colonizing (Michigan 2001) group B streptococcal 
isolates
Invasive isolates (n = 486) Colonizing isolates (n = 167)
Antibiotic Susceptible % Intermediate % Resistant % Susceptible % Intermediate % Resistant %
Amplicillin 100 0 0 100 0 0
Cefazolin 99.4 0.6 0 99.4 0.6 0
Clindamycin 80.0 0 20.0 59.3 0 40.71
Erythromycin 75.5 0 24.5 58.1 0 41.91
Imipenem 100 0 0 100 0 0
Levofloxacin 99.6 0 0.4 99.4 0 0.6
Linezolid 100 0 0 100 0 0
Penicillin 100 0 0 100 0 0
Quinupristin-dalfopristin 100 0 0 100 0 0
Vancomycin 100 0 0 100 0 0
1: Significantly different (P <.001) from the value for invasive isolatesBMC Infectious Diseases 2006, 6:57 http://www.biomedcentral.com/1471-2334/6/57
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between invasive strains isolated in different years. A
Fisher's Exact test was used to examine associations when
stratified data was sparse.
Results
We examined the antimicrobial susceptibility profile and
capsular type distribution for 486 invasive GBS isolates
and 167 isolates colonizing nonpregnant adults. Most
invasive strains were isolated from blood (88.4%) or CSF
(3.1%). Colonizing strains were isolated from the anal
orifice (59.3%), vagina (17.4%), urine (14.4%) or throat
(9.0%). All invasive and colonizing isolates, with the
exception of four cefazolin-intermediate isolates and
three levofloxacin-resistant isolates, were universally sus-
ceptible to ampicillin, cefazolin, imipenem, levofloxacin,
linezolid, penicillin, quinupristin-dalfopristin and vanco-
mycin (Table 1). Among invasive isolates, the MIC range
for clindamycin was 0.032 to > 256 µg/mL, while erythro-
mycin was 0.023 to > 256 µg/mL. MIC ranges were similar
for colonizing strains. 20.0% (97/486) of invasive and
40.7% (68/167) of colonizing isolates were resistant to
clindamycin (P < .001) and 24.5% (119/486) of invasive
and 41.9% (70/167) of colonizing isolates were resistant
to erythromycin (P < .001). 37.1% (36/97) of invasive
and 20.6% (14/68) of colonizing isolates resistant to clin-
damycin were identified by D-test. Furthermore, 19.8%
(96/486) of invasive and 38.3% (64/167) of colonizing
isolates were resistant to both clindamycin and erythro-
mycin (P  < .001). Slightly more clindamycin-resistant
invasive isolates were also resistant to erythromycin, when
compared to colonizing strains (99.0% vs. 94.1%, P = .09,
Fisher's exact test), whereas, a significantly greater number
of erythromycin-resistant colonizing strains were also
resistant to clindamycin, when compared to invasive iso-
lates (91.4% vs. 80.7%, P < .05).
Resistance by year of isolation
In 2001, the year colonizing isolates were collected,
24.8% (29/117) of invasive isolates and 40.7% (68/167)
of colonizing isolates were clindamycin-resistant (P  <
.01). During this same year 29.1% (34/117) of invasive
isolates and 41.9% (70/167) of colonizing isolates were
erythromycin-resistant (P < .05).
Among invasive strains, the frequency of clindamycin
resistance increased from 11.8% (4/34) in 1998 to 24.8%
(29/117) in 2001 and decreased slightly to 20.8% (31/
149) in 2002 (P = .37). Similarly, the frequency of eryth-
Clindamycin and erythromycin resistance among GBS invasive strains (n = 486) by year of isolation Figure 1
Clindamycin and erythromycin resistance among GBS invasive strains (n = 486) by year of isolation. Wisconsin, 1998 – 2002.
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romycin resistance increased from 17.6% (6/34) in 1998
to 29.1% (34/117) in 2001 and decreased slightly to
26.2% (39/149) in 2002 (P = .47) (Figure 1). Overall,
resistance frequencies among invasive isolates for each
year were lower when compared to colonizing isolates.
Thus, for the remainder of the analyses we compared col-
onizing isolates to all invasive isolates.
Resistance by capsular type
In general, most resistant isolates were resistant to both
clindamycin and erythromycin. Among invasive isolates,
resistance to both antimicrobial agents ranged from 3.4%
for type Ia strains to 39.4% for type V strains, and among
colonizing isolates resistance to both antimicrobial agents
ranged from 8.7% for type Ib strains to 63.3% for type V
strains (excluding type IV strains) (Table 2). Additionally,
the frequency of resistance to both antimicrobial agents
differed significantly between invasive and colonizing
strains for capsular types Ia, II, III and V.
39.4% (71/180) of invasive capsular type V strains and
63.3% (38/60) of colonizing type V strains were resistant
to clindamycin (P < .01). Furthermore, 41.7% (75/180) of
invasive capsular type V strains and 65.0% (39/60) of col-
onizing type V strains were resistant to erythromycin (P <
.01).
Resistance by age
The majority of invasive GBS isolates were from persons
50 years of age or older (65.4%) (Table 3). Resistance fre-
quencies were highest among persons 18–49 years and
were similar for infants with early-onset and late-onset
disease (Data not shown). When compared to colonizing
isolates from persons 18–19 years, resistance to clindamy-
Table 2: Clindamycin and erythromycin resistance among invasive (Wisconsin 1998–2002) and colonizing (Michigan 2001) group B 
streptococcal isolates by capsular type
Invasive isolates (n = 486)
Capsular type No. of strains Clindamycin resistance 
only no. (%)
Erythromycin 
resistance only no. (%)
Resistance to both no. 
(%)
Ia 118 0 14 (11.9) 4 (3.4)
Ib 54 0 0 8 (14.8)
II 65 0 3 (4.6) 7 (10.8)
III 62 1 (1.6) 2 (3.2) 5 (8.1)
IV 1000
V 180 0 4 (2.2) 71 (39.4)
VI 0000
VII 0000
VIII 0000
NT 3 0 0 1 (20.0)
VT 3000
Total 486 1 (0.2) 23 (4.7) 96 (19.8)
Colonizing isolates (n = 167)
Capsular type No. of strains Clindamycin resistance 
only no. (%)
Erythromycin 
resistance only no. (%)
Resistance to both no. 
(%)
Ia 31 2 (6.5) 3 (9.7) 7 (22.6)1
Ib 23 0 1 (4.4) 2 (8.7)
II 18 0 0 6 (33.3)1
III 22 2 (9.1) 0 6 (27.3)1
IV 2 0 0 2 (100)
V 60 0 1 (1.7) 38 (63.3)1
VI 0000
VII 0000
VIII 1000
NT 10 0 1 (10.0) 3 (30.0)
VT 0000
Total 167 4 (2.4) 6 (3.6) 64 (38.3)
1: Significantly different (P < .05) from the value for invasive isolates.BMC Infectious Diseases 2006, 6:57 http://www.biomedcentral.com/1471-2334/6/57
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cin (25.3% vs. 40.7%, P < .05) and erythromycin (32.2%
vs. 41.9%, P = .13) was notably lower among invasive iso-
lates from persons 18–49 years. Furthermore, 25.3% (22/
87) of invasive isolates from persons 18–49 years and
38.3% (64/167) of colonizing isolates were resistant to
both antimicrobial agents (P < .05). Because the sample
size of persons 18–29 years was inadequate to detect a sig-
nificant difference between the two populations we com-
bined the 18–29 year-old and 30–49 year-old age
categories, which displayed similar frequencies of clin-
damycin and erythromycin resistance, allowing us to
compare resistance levels for similar age groups.
Capsular type by age
Thirty-five percent (26/75) of invasive GBS isolates from
persons ≤ 1 year of age were capsular type Ia, followed by
type III (25.3%), and type V (20.0%) (Table 4). Similarly,
40.0% (2/5) of invasive isolates from persons 1–17 years
of age were capsular type Ia, followed by one isolate each
for types Ib, III, and V. Forty-one percent (164/402) of
invasive isolates from persons ≥ 18 years of age were cap-
sular type V, followed by type Ia (22.4%), and type II
(14.2%). Similarly, 35.9% (60/167) of colonizing GBS
isolates from persons 18–19 years of age were capsular
type V, followed by type Ia (18.6%), and type Ib (13.8%).
Resistance to other antimicrobial agents
We identified two invasive isolates and one colonizing
isolate resistant to levofloxacin, which has only recently
been described for GBS [22] (Data not shown). Invasive
isolates were capsular types V and III, and the colonizing
strain was type Ia. Invasive organisms were isolated from
blood and the colonizing strain, from urine. Patients with
invasive disease were 53- and 36-years of age, and their
isolates were collected in 2001 and 2002, respectively. The
colonized participant was 18-years of age and the year of
collection was 2001.
Additionally, we identified four strains with cefazolin-
intermediate resistance; all four strains were susceptible to
ampicillin and penicillin. Three of these isolates were
invasive isolates and one was a colonizing isolate. Each
isolate was capsular type V. Invasive organisms were iso-
lated from blood and bone cultures, and the colonizing
isolate was from the vagina. Infected patients were 2
months, 47- and 70-years of age, and their isolates were
collected in 1999, 2001 and 2000, respectively. The colo-
nized participant was 19-years of age and the year of col-
lection was 2001.
Discussion
In vitro resistance to clindamycin and erythromycin has
significantly increased since the implementation of IAP
neonatal disease prevention strategies in 1996 [6]. Fur-
thermore, cefazolin-intermediate resistance and levo-
floxacin [22] resistance among GBS has emerged.
Cefazolin-intermediate resistance is concerning given that
cefazolin is a first-generation cephalosporin, which shares
pharmacokinetic properties with penicillin [7]. Increased
and continued use of IAP, theoretically, may promote the
development of GBS resistance to penicillin. Therefore
IAP should be considered an interim solution to early-
onset GBS disease.
We observed resistance rates of 40.7% to clindamycin and
41.9% to erythromycin among GBS isolates colonizing
nonpregnant college students. Antimicrobial susceptibil-
ity profiles were quite similar by age, although levels of
clindamycin (25.3%) and erythromycin (32.2%) resist-
ance were highest among invasive isolates from persons
18–49 years of age with invasive GBS disease. This finding
is of great concern.
We also found an association between clindamycin and
erythromycin resistance and GBS capsular type V, which is
Table 3: Frequency of clindamycin and erythromycin resistance among invasive and colonizing group B streptococcal isolates by age
Invasive isolates (n = 486) Colonizing isolates1 (n = 167)
Age group (no.) Clindamycin resistance 
no. (%)
Erythromycin 
resistance no. (%)
Clindamycin resistance 
no. (%)
Erythromycin 
resistance no. (%)
< 1 (75) 16 (21.3) 18 (24.0) - -
1–17 (5) 1 (20.0) 1 (20.0) - -
18–29 (17) 5 (29.4) 6 (35.3) 68(40.7)2 70 (41.9)3
30–49 (70) 17 (24.3) 22 (31.4) - -
≥ 50 (315) 58 (18.4) 72 (22.9) - -
Total (482) 97 (20.1) 119 (24.7) 68 (40.7)2 70 (41.9)2
1: All colonizing isolates were from individuals 18–19 years of age.
2: Significantly different (P < .05) from the value for invasive isolates.
3: Not significantly different (P = .13) from the value for invasive isolates.BMC Infectious Diseases 2006, 6:57 http://www.biomedcentral.com/1471-2334/6/57
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consistent with previous reports [11,12,23-25]. Thirty-
nine percent and 41.7% of invasive capsular type V strains
were resistant to clindamycin and erythromycin, respec-
tively, compared to 63.3% and 65.0% among colonizing
type V strains. Capsular type V predominated among inva-
sive isolates from persons ≥ 18 years of age and colonizing
isolates from persons 18–19 years of age. It appears that
capsular type V strains contribute to the high resistance
rates in both populations. However, we did observe sig-
nificantly higher proportions of clindamycin and erythro-
mycin resistance among commensal than invasive isolates
of serotypes Ia, II and III. Whether this represents local
variation in resistance due to differences in antibiotic use,
or population structure is uncertain. Nonetheless, the
observation that resistance rates can exceed one-third of
all strains – whether in colonizing or invasive isolates, is
troubling.
Our comparison was limited in that the populations were
not from the same geographic location, they had a differ-
ent age distribution and isolates were collected over a sim-
ilar but not identical time period. To ameliorate these
inequalities we examined both populations for 2001 and
compared antimicrobial resistance frequencies across sim-
ilar age groups. Local variations in resistance may exist,
therefore higher levels of resistance among colonizing iso-
lates may reflect local variation. Furthermore, invasive iso-
lates were collected through surveillance and colonizing
strains as part of a cross sectional survey. Our cross sec-
tional population was young (18–19 years), primarily
white and from middle or upper income levels, poten-
tially limiting our generalizability.
Conclusion
Levels of clindamycin and erythromycin resistance were
high among isolates colonizing nonpregnant college stu-
dents and invasive GBS isolates, particularly though
among the colonizing isolates. Comparisons between
similar populations yielding colonizing and invasive
strains would be helpful to further examine this issue.
High level antimicrobial resistance among colonized,
nonpregnant college students is likely driven by antibiotic
use, coupled with high transmission probabilities. How-
ever, further analyses are needed to identify predictors of
resistance among this population. Our current findings
highlight the need for routine susceptibility testing of
GBS, particularly in individuals with penicillin allergy, to
ensure proper therapy.
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